Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs

NCT ID NCT07816185

Disease control Sponsor: Pulmovant, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing an inhaled drug called mosliciguat in people who have pulmonary hypertension caused by interstitial lung disease, a condition where lung scarring leads to high blood pressure in the lungs. The phase 3 trial enrolls about 376 participants who receive either mosliciguat or a placebo through a dry powder inhaler. The main goal is to see whether the drug improves how far participants can walk in six minutes, with a secondary aim of delaying hospitalizations or other signs of worsening.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an inhaled drug called mosliciguat
What this could lead to
If it works, inhaled mosliciguat could become a new treatment option for people whose pulmonary hypertension is caused by interstitial lung disease, a group with few targeted therapies.
What could go wrong
The trial is still testing whether the drug helps, and inhaled therapies for this condition have failed before. Mosliciguat may not improve walking distance or delay worsening, and it could cause side effects such as coughing, low blood pressure, or breathing problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 376 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants willing and able to provide informed consent. * Participants with diagnosis of pulmonary hypertension (PH) associated with interstitial lung disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed disease include: 1. Idiopathic interstitial pneumonia (IIP) 2. Chronic Hypersensitivity pneumonitis 3. ILD associated connective tissue disease (CTD) * Confirmed pulmonary hypertension by right heart catheterization (RHC). * Ability to perform 6-minute walk distance ≥100 meters. Exclusion Criteria: * Diagnosis of PH Group 1 (eg, pulmonary arterial hypertension), Group 2 (related to left heart disease), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified). * Exacerbation of underlying lung disease requiring change in therapy or hospitalization within 28 days prior to randomization * Receiving \>10 L/min oxygen supplementation by any mode of delivery at rest * History of intolerance to mosliciguat, or sGC stimulators or activators. * Initiation of pulmonary rehabilitation or ongoing acute phase of rehabilitation within 28 days prior to randomization. * Receipt of investigational or interventional therapy within 42 days OR 5 half-lives (whichever is longer) prior to randomization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Fibrosis interstitial lung disease pulmonary hypertension pulmonary hypertension owing to lung disease and/or hypoxia vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Fibrosis Interstitial lung disease Pulmonary hypertension Vascular diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Clinical Research Site

    RECRUITING

    Kissimmee, Florida, 34746, United States

  • Clinical Research Site

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • Clinical Research Site

    RECRUITING

    Bend, Oregon, 97701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.